RLAY
Relay Therapeutics, Inc.Company Information
- Company Name
- Relay Therapeutics, Inc.
- CIK
- CIK0001812364
- Category
- Large accelerated filer
- Ticker: Exchange
- RLAY: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- RLAY
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 6,779,889
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 236,767,002
- Shares outstanding
- 202,849,466
- Ownership
- 116.72%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -4.96%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 121 | 205 | 84 | 92 | 114 | 94 | 124 | 152 | 134 | 153 | 144 | 151 | ||||||
| Investments | 790 | 437 | 471 | 505 | 543 | 617 | 657 | 687 | 554 | 597 | 606 | 659 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 928 | 658 | 578 | 624 | 680 | 740 | 809 | 865 | 704 | 770 | 770 | 832 | ||||||
| Prepaid Expense Current | 9 | 12 | 18 | 24 | 16 | 22 | 17 | 19 | 10 | 13 | 17 | 17 | ||||||
| Other Assets Current | 8 | 5 | 6 | 4 | 8 | 7 | 11 | 7 | 6 | 7 | 3 | 4 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 2 | 2 | 3 | 5 | 6 | 7 | 8 | 10 | 11 | 11 | ||||||
| Operating Lease Right Of Use Asset | 37 | 39 | 40 | 41 | 43 | 50 | 52 | 53 | 55 | 56 | 58 | 59 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | 2 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | - | - | 0 | 0 | 0 | 2 | 2 | - | - | - | 2 | - | ||||||
| Assets | 967 | 700 | 621 | 670 | 729 | 799 | 871 | 930 | 773 | 841 | 844 | 907 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 11 | 4 | 8 | 3 | 5 | 8 | 14 | 7 | 11 | 8 | 9 | 13 | ||||||
| Accrued Liabilities Current | 34 | 21 | 14 | 25 | 23 | 21 | 21 | 33 | 28 | 22 | 15 | 31 | ||||||
| Operating Lease Liability Current | 4 | 4 | 4 | 4 | 4 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 51 | 30 | 26 | 33 | 33 | 37 | 51 | 47 | 45 | 37 | 30 | 51 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | 8 | - | - | - | - | 0 | ||||||
| Other Liabilities Current | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 27 | 28 | 29 | 30 | 31 | 41 | 43 | 44 | 46 | 47 | 49 | 50 | ||||||
| Liabilities | 77 | 57 | 54 | 62 | 63 | 78 | 94 | 91 | 91 | 96 | 92 | 129 | ||||||
| Business Combination Contingent Consideration Liability | - | - | 0 | - | - | - | 0 | - | - | 11 | 13 | 28 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 890 | 642 | 567 | 608 | 666 | 721 | 778 | 839 | 682 | 746 | 752 | 778 | ||||||
| Additional Paid In Capital | 3,063 | 2,730 | 2,581 | 2,567 | 2,551 | 2,536 | 2,517 | 2,498 | 2,257 | 2,229 | 2,153 | 2,099 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -0 | 1 | 0 | -0 | 0 | -1 | 3 | -1 | -1 | -0 | -3 | ||||||
| Retained Earnings Accumulated Deficit | -2,172 | -2,088 | -2,015 | -1,960 | -1,886 | -1,815 | -1,738 | -1,662 | -1,574 | -1,482 | -1,401 | -1,317 | ||||||
| Liabilities And Stockholders Equity | 967 | 700 | 621 | 670 | 729 | 799 | 871 | 930 | 773 | 841 | 844 | 907 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 450 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 219 | 189 | 174 | 173 | 172 | 170 | 168 | 167 | 133 | 132 | 127 | 123 | ||||||
| Shares Outstanding | 219 | 189 | 174 | 173 | 172 | 170 | 168 | 167 | 133 | 132 | 127 | 123 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRelay Therapeutics, Inc. (RLAY) — SEC Financial Statements & Analysis
Relay Therapeutics, Inc. (RLAY) is a biological products, (no diagnostic substances) company, incorporated in DE. Relay Therapeutics, Inc. trades on Nasdaq as: RLAY. Relay Therapeutics, Inc. (RLAY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Relay Therapeutics, Inc. carries a market cap of $3.80B, a P/E ratio of -13.27x, a P/B ratio of 4.26x, a P/S ratio of 366.73x, an enterprise value of $3.67B, and an EV/EBITDA multiple of -11.95x. On profitability, it posts an operating margin of -2999.67%, a net margin of -2763.91%, a Return on Equity (ROE) of -36.77%, a Return on Assets (ROA) of -33.72%, and a Return on Invested Capital (ROIC) of -47.08%. Per share, it reports EPS of $-1.41, free cash flow per share of $-1.05, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 23.85% year-over-year, net income growth of -8.19% year-over-year, and EPS growth of -22.48% year-over-year. On the balance sheet, it maintains a current ratio of 18.27x, a quick ratio of 18.10x, working capital of $877.28M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-212.21M (TTM), and net debt of $-121.19M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.80B
- P/E TTM
- -13.27x
- EPS TTM
- $-1.41
- P/B TTM
- 4.26x
- ROE TTM
- -36.77%
- ROA TTM
- -33.72%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-212.21M
- Net Revenue TTM Growth 1Y
- 23.85%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Relay Therapeutics, Inc. in?
Relay Therapeutics, Inc. (RLAY) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does RLAY trade on?
Relay Therapeutics, Inc. (RLAY) trades on the Nasdaq.
Where is Relay Therapeutics, Inc. incorporated?
Relay Therapeutics, Inc. is incorporated in DE.
When was Relay Therapeutics, Inc. (RLAY)'s most recent SEC filing?
Relay Therapeutics, Inc. (RLAY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is RLAY's market cap?
Relay Therapeutics, Inc. (RLAY) has a market capitalization of $3.80B as of 2026-06-30.
What is RLAY's EPS (earnings per share)?
Relay Therapeutics, Inc. (RLAY)'s trailing twelve month EPS is $-1.41 as of 2026-06-30.
What is RLAY's ROE (return on equity)?
Relay Therapeutics, Inc. (RLAY)'s trailing twelve month Return on Equity (ROE) is -36.77% as of 2026-06-30.
What is RLAY's ROA (return on assets)?
Relay Therapeutics, Inc. (RLAY)'s trailing twelve month Return on Assets (ROA) is -33.72% as of 2026-06-30.
What is RLAY's ROIC (return on invested capital)?
Relay Therapeutics, Inc. (RLAY)'s trailing twelve month Return on Invested Capital (ROIC) is -47.08% as of 2026-06-30.
What is RLAY's EV/EBITDA?
Relay Therapeutics, Inc. (RLAY)'s trailing twelve month EV/EBITDA is -11.95x as of 2026-06-30.